S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
NASDAQ:RANI

Rani Therapeutics (RANI) Stock Price, News & Analysis

$3.69
-0.05 (-1.34%)
(As of 03/1/2024 ET)
Today's Range
$3.63
$3.80
50-Day Range
$2.98
$3.80
52-Week Range
$1.82
$6.89
Volume
139,498 shs
Average Volume
75,050 shs
Market Capitalization
$184.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.25

Rani Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
340.4% Upside
$16.25 Price Target
Short Interest
Bearish
14.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.04mentions of Rani Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$35,550 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.39) to ($1.44) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.64 out of 5 stars

Medical Sector

696th out of 950 stocks

Pharmaceutical Preparations Industry

327th out of 440 stocks


RANI stock logo

About Rani Therapeutics Stock (NASDAQ:RANI)

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.

RANI Stock Price History

RANI Stock News Headlines

Rani Therapeutics (NASDAQ:RANI) Shares Down 1.3%
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Rani Therapeutics Holdings Inc Class A
See More Headlines
Receive RANI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/22/2023
Today
3/03/2024
Next Earnings (Estimated)
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RANI
Fax
N/A
Employees
163
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.25
High Stock Price Target
$24.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+340.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-30,590,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.72 million
Book Value
$1.50 per share

Miscellaneous

Free Float
24,989,000
Market Cap
$184.50 million
Optionable
Optionable
Beta
0.97
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Mir A. Imran (Age 68)
    Executive Chairman
    Comp: $80k
  • Mr. Talat Imran (Age 42)
    CEO & Director
    Comp: $827k
  • Mr. Svai S. Sanford (Age 54)
    Chief Financial Officer
    Comp: $661.6k
  • Dr. Mir Hashim (Age 64)
    Chief Scientific Officer
    Comp: $661.6k
  • Mr. Eric Groen (Age 53)
    General Counsel
  • Ms. Bella Vazquez
    Vice President of Human Resources
  • Ms. Kate McKinley M.B.A.
    Chief Business Officer














RANI Stock Analysis - Frequently Asked Questions

Should I buy or sell Rani Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rani Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RANI shares.
View RANI analyst ratings
or view top-rated stocks.

What is Rani Therapeutics' stock price target for 2024?

5 analysts have issued 12-month price targets for Rani Therapeutics' stock. Their RANI share price targets range from $8.00 to $24.00. On average, they expect the company's stock price to reach $16.25 in the next twelve months. This suggests a possible upside of 340.4% from the stock's current price.
View analysts price targets for RANI
or view top-rated stocks among Wall Street analysts.

How have RANI shares performed in 2024?

Rani Therapeutics' stock was trading at $3.32 at the beginning of 2024. Since then, RANI stock has increased by 11.1% and is now trading at $3.69.
View the best growth stocks for 2024 here
.

When is Rani Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our RANI earnings forecast
.

How were Rani Therapeutics' earnings last quarter?

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) posted its earnings results on Wednesday, March, 22nd. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.01. During the same quarter in the previous year, the firm posted ($0.27) earnings per share.

When did Rani Therapeutics IPO?

(RANI) raised $100 million in an initial public offering on Friday, July 30th 2021. The company issued 6,666,667 shares at $14.00-$16.00 per share.

Who are Rani Therapeutics' major shareholders?

Rani Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Alpha Square Group S LLC (0.12%), Stifel Financial Corp (0.10%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Cortes Isidoro Alfonso Quiroga, Maulik Nanavaty, Mir A Imran, South Cone Investments Limited and Talat Imran.
View institutional ownership trends
.

How do I buy shares of Rani Therapeutics?

Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RANI) was last updated on 3/3/2024 by MarketBeat.com Staff